AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04059458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
Description: Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.
Study NCT00988442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced nursing telephone support
Description: Weekly phone calls by study nurses for 8 weeks and then calls every 2 weeks for 40 weeks; nurses could schedule more frequent calls at their discretion. Calls provided information, motivational enhancement, problem-solving skills, and affective support.
Study NCT00988442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Usual ACTG site care.
Study NCT00988442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Usual ACTG site care.
Study NCT04509882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bear bile pill
Description: Bear bile pill (15 pills) taken orally three times a day after meals with water.
Study NCT04509882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo(15 pills) taken orally three times a day after meals with water.
Study NCT03174262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ergonomic Computer Workstation Training
Description: Training in proper body alignment and use of computer at computer workstations for people who spend 30% or more of a typical day at a computer. Training consists of learning proper positioning for head, neck, shoulders, arms, hands, and legs; proper arrangement of computer monitor, keyboard, mouse, and accessories.
Study NCT02357563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulipristal acetate
Description: 5 mg/day will be administered starting from day 1 of the cycle and up to three months later for two courses, with an interval between the courses of 1 month
Study NCT02357563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24) and repeated 3 months later
Study NCT00022542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT02093130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice
Study NCT02093130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03499886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride 50Mg/1mL Solution for Injection
Description: In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
Study NCT03499886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hcl 50Mg/Ml Inj
Description: In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
Study NCT02539862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy online
Description: The cognitive behavioral therapy online program is delivered through an accessible web application on a web browser with a personal password
Study NCT01534286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theramine
Description: Theramine 2 capsules 3 times per day
Study NCT01534286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Theramine- like placebo
Description: Theramine-like placebo capsules 2 three times daily
Study NCT03322124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octenidinedihydrochlorid
Description: Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
Study NCT03322124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
Study NCT03063866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 1 mg/kg i.v
Study NCT03063866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 3 mg i.v
Study NCT03063866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl 0.5 ug/kg
Study NCT02917629 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02842788 — intervention group
Intervention type: PROCEDURE
Intervention: Prone positioning
Description: Turning the patient face down for several consecutive hours
Study NCT04758416 — intervention group
Intervention type: PROCEDURE
Intervention: biopsy or surgical pathology in metastases
Description: biopsy or surgical pathology in extrahepatic/liver/brain metastases
Study NCT04758416 — intervention group
Intervention type: DRUG
Intervention: 68Ga-HER2 affibody,18F-FDG, 18F-FES
Description: 68Ga-NOTA-MAL-MZHER2 (68Ga-HER2) affibody is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
Study NCT01738438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Study NCT01704196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepicastat
Description: 120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.
Study NCT01704196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02910713 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intranasal Tear Neurostimulator
Description: The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
Study NCT02910713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Tear Neurostimulator
Description: The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
Study NCT03189472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: low amplitude direct currents to induce changes in cortical excitability. tDCS produces current intensities in the brain orders of magnitude below other stimulation techniques such as transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT)
Study NCT03189472 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The device will be programmed to deliver either active or sham tDCS (all study personnel and participants will be blinded), and operated with unlock codes provided by the study technician daily to release one session
Study NCT01425749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recMAGE-A3 + AS15 ASCI
Description: Injections of recMAGE-A3 + AS15 ASCI will be given 5 times at 3-week intervals. This will either be administered cutaneously or intramuscularly depending on the study group. The injected doses will be administered in alternating extremities at each visit.
Study NCT03044470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Role of cryotherapy in reduction of post operative pain
Study NCT03731546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping
Description: Cord clamping 60 seconds after delivery of fetus in preterm infants
Study NCT03864536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Prescriptions
Description: Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
Study NCT03864536 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Prescriptions
Description: Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
Study NCT02253017 — intervention group
Intervention type: OTHER
Intervention: Children operated on for cataract
Description: Compilation of results of monitoring of children aged 8 to 10 months, 3 years, 5 years, 8 years
Study NCT01459068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach
Description: CETA components include:~1. Engagement (encouraging participation)~2. Psychoeducation (introduction)~3. Anxiety Management Strategies (relaxation)~4. Behavioral Activation (getting active)~5. Cognitive Coping/Restructuring (thinking in a different way, part I and part II)~6. Imaginal Gradual Exposure (talking about difficult memories)~7. In Vivo Exposure (Live exposure)~8. Suicide/Homicide/Danger Assessment and Planning (safety)~9. Screening and Brief Intervention for Alcohol (alcohol intervention)
Study NCT03067844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
Study NCT03067844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alirocumab
Description: Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
Study NCT03339401 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
Study NCT03339401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Description: Brincidofovir (BCV) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
Study NCT00638417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maximal strength training
Description: maximal dynamic strength training from 1 week after the operation, 5 training bouts a week for 4 weeks. The regimen consisted of 2 exercises, leg press and hip abduction, that included 4 series of 5RM involving the operated leg only. 5RM corresponds to approximately 85% of 1RM. When the patients managed to perform 6RM, the load was increased by 5kg. The series were separated by resting periods of 2 minutes.
Study NCT00638417 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: conventional rehabilitation
Description: conventional rehabilitation program: inpatient treatment in a rehabilitation center. Individual sling exercise therapy in hip abduction/adduction, hip flexion/extension, exercises with low resistance (>12-15 repetitions37), or no resistance and exercises performed in water when sutures had been removed. Each session lasted 1 hour and was performed 5 days a week for 4 weeks.
Study NCT00638417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation
Description: conventional rehabilitation program: inpatient treatment in a rehabilitation center. Individual sling exercise therapy in hip abduction/adduction, hip flexion/extension, exercises with low resistance (>12-15 repetitions37), or no resistance and exercises performed in water when sutures had been removed. Each session lasted 1 hour and was performed 5 days a week for 4 weeks.
Study NCT01972594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targetted protocol with pedometer
Description: 12 week protocol based on targetted steps are given to the patient along with a pedometer.
Study NCT01972594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer(ActivPAL)
Study NCT03156855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14-day sequential therapy
Description: D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
Study NCT00480831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose
Study NCT00480831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: Intravenous repeating dose
Study NCT00480831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Intravenous repeating dose
Study NCT00480831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Intravenous repeating dose
Study NCT00480831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose
Study NCT00480831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: Intravenous repeating dose
Study NCT00480831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study NCT00480831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO95780
Description: Intravenous repeating dose
Study NCT03156855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth quadruple therapy
Description: D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
Study NCT02384304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice
Description: A self help program consisting of 8 modules and access to therapist guidance either through messages or through chat sessions
Study NCT00881530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 high dose once daily
Study NCT00881530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: open label comparator
Study NCT00881530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 low dose once daily
Study NCT00881530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: open label comparator
Study NCT00924794 — intervention group
Intervention type: PROCEDURE
Intervention: Cancer Registry of Norway (database)
Description: Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
Study NCT00599352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: magnesium
Description: Single infusion of elemental magnesium given over 4 hours, 0.2mEq/kg (2.4 mg/kg)
Study NCT03686930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 1 - FP-045 oral solution
Description: FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
Study NCT03686930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 2 - FP-045 oral solution
Description: FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
Study NCT02384304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages
Description: A self help program consisting of 8 modules and access to therapist guidance through messages
Study NCT03686930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 3 - FP-045 oral solution
Description: FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
Study NCT03686930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for FP-045 oral solution)
Description: Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
Study NCT02384304 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self help
Description: A self help program consisting of 8 modules
Study NCT00967057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT00967057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given intramuscularly
Study NCT00967057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00851370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair)
Description: Bi-weekly
Study NCT01123031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole
Description: lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
Study NCT01123031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
Study NCT04133662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Manipulation Protocol
Description: A structured sleep duration intervention will be taught to patients
Study NCT02655276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microencapsulated Glycine
Description: 100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.
Study NCT02655276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Description: Placebo t.i.d. from Biotiki® in a crossover-design.
Study NCT04556357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
Study NCT04556357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
Study NCT02663427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: serological examination and gastroscope
Study NCT02967419 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Study NCT00886327 — intervention group
Intervention type: PROCEDURE
Intervention: Colonic capsule endoscopy
Study NCT00787839 — intervention group
Intervention type: OTHER
Intervention: Glucose challenge test
Description: At a first outpatient visit, at different times of the day and without a prior fast, subjects will have a 50 gram glucose drink followed by measurement of plasma and capillary glucose along with A1c one hour later. They will also fill out questionnaires. At a second outpatient visit, in the morning after fasting overnight, they will have a 75 gram oral glucose tolerance test.
Study NCT00787839 — intervention group
Intervention type: OTHER
Intervention: Glucose tolerance test
Description: Subjects found to have diabetes or prediabetes on the initial glucose tolerance test may be requested to have a repeat glucose tolerance test and A1c.
Study NCT00298298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-Vax: Autologous, DNP-Modified NSCLC Vaccine
Description: autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
Study NCT02902445 — intervention group
Intervention type: BIOLOGICAL
Intervention: rotavirus rapid screen test
Description: According to routine care
Study NCT02902445 — intervention group
Intervention type: GENETIC
Intervention: polymorphism exploration
Description: from an oral swab collected after parents consent
Study NCT02968498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose crystals 10 g
Description: White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
Study NCT02968498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose crystals 20 g
Description: White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
Study NCT02968498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose liquid 10 g
Description: Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
Study NCT02968498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose liquid 20 g
Description: Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
Study NCT02968498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose 20 g
Description: White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
Study NCT02968498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Still water
Description: Still water will be used. Water from the same source will be also used to dissolve investigational and control products.